|
1.
|
Lim B, Cream LV, Harvey HA. Update on clinical trials: genetic targets in breast cancer. Adv Exp Med Biol. 2013; 779:35-54.
|
|
|
|
|
2.
|
Cheng Y, Ren X, Zhang Y, Shan Y, Huber-Keener KJ, Zhang L, Kimball SR, Harvey H, Jefferson LS, Yang JM. Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells. Autophagy. 2013 Feb 1; 9(2):208-19.
|
|
|
|
|
3.
|
Faltas B, Zeidan A, Peters K, Das A, Joudeh J, Navaraj A, Dolloff NG, Harvey HA, Jiang Y, Allen JE, Dicker DT, El Deiry WS. Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J Clin Oncol. 2011 Jul 20; 29(21):2946-7; author reply 2947-8.
|
|
|
|
|
4.
|
Sivendran S, Harvey H, Lipton A, Drabick J. Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series. Int J Hematol. 2011 Jun; 93(6):782-6.
|
|
|
|
|
5.
|
Deshaies I, Cherenfant J, Gusani NJ, Jiang Y, Harvey HA, Kimchi ET, Kaifi JT, Staveley-O'Carroll KF. Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment. Ther Clin Risk Manag. 2010; 6:453-8.
|
|
|
|
|
6.
|
Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol. 2010 Apr; 44(4):286-8.
|
|
|
|
|
7.
|
Lipton A, Campbell-Baird C, Harvey H, Kim C, Demers L, Costa L. Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases. Am J Clin Oncol. 2010 Feb; 33(1):75-8.
|
|
|
|
|
8.
|
Harvey HA, Cream Lv. Biology of bone metastases: causes and consequences. Clin Breast Cancer. 2007 Jul; 7 Suppl 1:S7-S13.
|
|
|
|
|
9.
|
Harvey HA, Kimura M, Hajba A. Toremifene: an evaluation of its safety profile. Breast. 2006 Apr; 15(2):142-57.
|
|
|
|
|
10.
|
Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer. 2005 Jul 15; 104(2):257-63.
|
|
|
|
|
11.
|
Lipton A, Harvey H, Witters L, Kerr S, Legore K, Campbell C. Gemcitabine/Irinotecan/celecoxib in pancreatic cancer. Oncology (Williston Park). 2004 Dec; 18(14 Suppl 14):43-5.
|
|
|
|
|
12.
|
Harvey HA. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Semin Oncol. 2004 Dec; 31(6 Suppl 12):23-30.
|
|
|
|
|
13.
|
Harvey HA, Almokadem SM. Hypercalcemia and gallium nitrate. J Support Oncol. 2004 Nov-Dec; 2(6):516-7.
|
|
|
|
|
14.
|
Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N, Engle L, Chinchilli V, Costa L, Brady C, Seaman J, Lipton A. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol. 2004 Mar; 15(3):455-9.
|
|
|
|
|
15.
|
Smith JP, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin PJ, Zagon IS. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs. 2004 Mar; 15(3):203-9.
|
|
|
|
|
16.
|
Ali SM, Harvey HA, Lipton A. Metastatic breast cancer: overview of treatment. Clin Orthop Relat Res. 2003 Oct; (415 Suppl):S132-7.
|
|
|
|
|
17.
|
Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol. 2003 May 15; 21(10):1967-72.
|
|
|
|
|
18.
|
Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Carney W, Allard JW, Lipton A. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem. 2002 Aug; 48(8):1314-20.
|
|
|
|
|
19.
|
Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002 Mar 15; 20(6):1467-72.
|
|
|
|
|
20.
|
Harvey HA, Jennings MP, Campbell CA, Williams R, Apicella MA. Receptor-mediated endocytosis of Neisseria gonorrhoeae into primary human urethral epithelial cells: the role of the asialoglycoprotein receptor. Mol Microbiol. 2001 Nov; 42(3):659-72.
|
|
|
|
|
21.
|
Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, Costa L, Lipton A. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol. 2001 Jul 15; 19(14):3434-7.
|
|
|
|
|
22.
|
Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res. 2001 Mar; 7(3):478-85.
|
|
|
|
|
23.
|
Harvey HA, Porat N, Campbell CA, Jennings M, Gibson BW, Phillips NJ, Apicella MA, Blake MS. Gonococcal lipooligosaccharide is a ligand for the asialoglycoprotein receptor on human sperm. Mol Microbiol. 2000 Jun; 36(5):1059-70.
|
|
|
|
|
24.
|
Martin JL, Harvey HA, Lipton A, Martin R. Combined chemoradiotherapy for unresectable pancreatic cancer. Am J Clin Oncol. 1999 Jun; 22(3):309-14.
|
|
|
|
|
25.
|
Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer. 1999 Mar; 6(1):75-92.
|
|
|
|
|
26.
|
Costa LA, Kopreski MS, Demers LM, Chinchilli VM, Santen RJ, Harvey HA, Lipton A. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma. Cancer. 1999 Jan 1; 85(1):100-3.
|
|
|
|
|
27.
|
Harvey HA. Emerging role of aromatase inhibitors in the treatment of breast cancer. Oncology (Williston Park). 1998 Mar; 12(3 Suppl 5):32-5.
|
|
|
|
|
28.
|
Harvey HA. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma. Cancer. 1997 Oct 15; 80(8 Suppl):1646-51.
|
|
|
|
|
29.
|
Eskander ED, Harvey HA, Givant E, Lipton A. Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2. Am J Clin Oncol. 1997 Oct; 20(5):511-4.
|
|
|
|
|
30.
|
Hopper KD, Kasales CJ, Eggli KD, TenHave TR, Belman NM, Potok PS, Van Slyke MA, Olt GJ, Close P, Lipton A, Harvey HA, Hartzel JS. The impact of 2D versus 3D quantitation of tumor bulk determination on current methods of assessing response to treatment. J Comput Assist Tomogr. 1996 Nov-Dec; 20(6):930-7.
|
|
|
|
|
31.
|
Harvey HA. Aromatase inhibitors in clinical practice: current status and a look to the future. Semin Oncol. 1996 Aug; 23(4 Suppl 9):33-8.
|
|
|
|
|
32.
|
Kumar R, Mandal M, Lipton A, Harvey H, Thompson CB. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res. 1996 Jul; 2(7):1215-9.
|
|
|
|
|
33.
|
Harvey HA, Lipton A. The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. Support Care Cancer. 1996 May; 4(3):213-7.
|
|
|
|
|
34.
|
Kopreski MS, Lipton A, Harvey HA, Kumar R. Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines. Anticancer Res. 1996 Jan-Feb; 16(1):433-6.
|
|
|
|
|
35.
|
Belman N, Bonnem EM, Harvey HA, Lipton A. Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma. Invest New Drugs. 1996; 14(4):387-9.
|
|
|
|
|
36.
|
Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 1995 Nov; 13(11):2722-30.
|
|
|
|
|
37.
|
Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol. 1995 May; 13(5):1129-35.
|
|
|
|
|
38.
|
Witters LM, Curley EM, Kumar R, Chinchilli VM, Harvey JP, Crebbin V, Harvey HA, Lipton A. Epidermal growth factor receptor ectodomain in the urine of patients with squamous cell carcinoma. Clin Cancer Res. 1995 May; 1(5):551-7.
|
|
|
|
|
39.
|
Lipton A, Demers LM, Harvey HA, Kambic KB, Grossberg H, Brady C, Adlercruetz H, Trunet PF, Santen RJ. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer. 1995 Apr 15; 75(8):2132-8.
|
|
|
|
|
40.
|
Harvey HA. The management of hypercalcemia of malignancy. Support Care Cancer. 1995 Mar; 3(2):123-9.
|
|
|
|
|
41.
|
Masamura S, Adlercreutz H, Harvey H, Lipton A, Demers LM, Santen RJ, Santner SJ. Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat. 1995; 33(1):19-26.
|
|
|
|
|
42.
|
Lipton A, Glover D, Harvey H, Grabelsky S, Zelenakas K, Macerata R, Seaman J. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol. 1994; 5 Suppl 7:S31-5.
|
|
|
|
|
43.
|
Lipton A, Demers L, Daniloff Y, Curley E, Hamilton C, Harvey H, Witters L, Seaman J, Van der Giessen R, Seyedin S. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem. 1993 Apr; 39(4):614-8.
|
|
|
|
|
44.
|
Demers LM, Lipton A, Harvey HA, Kambic KB, Grossberg H, Brady C, Santen RJ. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J Steroid Biochem Mol Biol. 1993 Mar; 44(4-6):687-91.
|
|
|
|
|
45.
|
Demers LM, Lipton A, Harvey HA, Hanagan J, Mulagha M, Santen RJ. The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. J Steroid Biochem Mol Biol. 1993 Mar; 44(4-6):683-5.
|
|
|
|
|
46.
|
Lipton A, Harvey H, Givant E, Hopper K, Lawler J, Matthews Y, Hirsh M, Zeffren J. Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma. J Immunother Emphasis Tumor Immunol. 1993 Feb; 13(2):122-9.
|
|
|
|
|
47.
|
Miele ME, Vesell ES, Ehmann WC, Lipton A, Harvey H, Kan NC. Hormonal and immunological regulation of 2', 5'-oligoadenylate synthetase activity in human peripheral blood mononuclear cells. Clin Immunol Immunopathol. 1992 Nov; 65(2):183-92.
|
|
|
|
|
48.
|
Lipton A, Santen RJ, Santner SJ, Harvey HA, Sanders SI, Matthews YL. Prognostic value of breast cancer aromatase. Cancer. 1992 Oct 1; 70(7):1951-5.
|
|
|
|
|
49.
|
Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol. 1992 Sep; 10(9):1436-43.
|
|
|
|
|
50.
|
Heitjan DF, Houts PS, Harvey HA. A decision-theoretic evaluation of early stopping rules. Stat Med. 1992 Mar; 11(5):673-83.
|
|
|
|
|
51.
|
Leitzel K, Bryce W, Tomita J, Manderino G, Tribby I, Thomason A, Billingsley M, Podczaski E, Harvey H, Bartholomew M, et al. Elevated plasma platelet-derived growth factor B-chain levels in cancer patients. Cancer Res. 1991 Aug 15; 51(16):4149-54.
|
|
|
|
|
52.
|
Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol. 1991 Jul; 9(7):1151-6.
|
|
|
|
|
53.
|
Santen RJ, Demers LM, Lynch J, Harvey H, Lipton A, Mulagha M, Hanagan J, Garber JE, Henderson IC, Navari RM, et al. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endocrinol Metab. 1991 Jul; 73(1):99-106.
|
|
|
|
|
54.
|
Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M. Somatostatin analogues in the treatment of breast and prostate cancer. J Steroid Biochem Mol Biol. 1990 Dec 20; 37(6):1083-7.
|
|
|
|
|
55.
|
Hirsh M, Lipton A, Harvey H, Givant E, Hopper K, Jones G, Zeffren J, Levitt D. Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy. J Clin Oncol. 1990 Oct; 8(10):1657-63.
|
|
|
|
|
56.
|
Stryker JA, Harvey HA, Houck JR, Manders EK, Bradfield JJ. Advanced head and neck cancer: low-dose, split-course radiation therapy and simultaneous infusion of 5-fluorouracil and cisplatin. Radiology. 1990 Aug; 176(2):567-71.
|
|
|
|
|
57.
|
Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev. 1990 May; 11(2):221-65.
|
|
|
|
|
58.
|
Demers LM, Melby JC, Wilson TE, Lipton A, Harvey HA, Santen RJ. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. J Clin Endocrinol Metab. 1990 Apr; 70(4):1162-6.
|
|
|
|
|
59.
|
Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulagha MT, Kochak GM, Fitzsimmons S, Sanders SI, Santen RJ. A phase I trial of CGS 16949A. A new aromatase inhibitor. Cancer. 1990 Mar 15; 65(6):1279-85.
|
|
|
|
|
60.
|
Lipton A, Harvey HA, Santen RJ, Stryker JA, Barnes SG, Walker BK, Dixon RH, Givant EM, Bartholomew MJ, Nadjafi C. FAM chemotherapy +/- aminoglutethimide in the treatment of pancreatic carcinoma. Eur J Surg Oncol. 1990 Feb; 16(1):12-4.
|
|
|
|
|
61.
|
Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat. 1989 Dec; 14(3):289-98.
|
|
|
|
|
62.
|
Lipton A, Harvey HA, Walker B, Dixon R, Valdivia D, Barnes S, Gordon R, White-Hershey D, Bartholomew MJ, Warzawski N, et al. Chemotherapy plus RA233 in the treatment of oat cell lung cancer. Am J Clin Oncol. 1989 Jun; 12(3):259-63.
|
|
|
|
|
63.
|
Lipton A, Harvey HA, Glenn J, Weidner WA, Strauss M, Miller SE, Taylor JB, White-Hershey D, Barlow JL. A phase I study of hepatic arterial infusion using difluoromethylornithine. Cancer. 1989 Feb 1; 63(3):433-7.
|
|
|
|
|
64.
|
Romano PJ, Lipton A, Harvey HA, Bartholomew MJ, Giudice G, Kloszewski F, Witkowski L, Downing MR. Immunologic monitoring studies in advanced cancer patients treated with recombinant human gamma interferon (IFN-gamma 4A). Mol Biother. 1989; 1(4):208-12.
|
|
|
|
|
65.
|
Santen RJ, Demers LM, Adlercreutz H, Harvey H, Santner S, Sanders S, Lipton A. Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocrinol Metab. 1989 Jan; 68(1):99-106.
|
|
|
|
|
66.
|
Foon K, Doroshow J, Bonnem E, Fefer A, Graham S, Grosh B, Narayan P, Elias L, Harvey H, Schulof R, et al. A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod. 1988 Dec; 7(6):540-5.
|
|
|
|
|
67.
|
Santen RJ, Santner SJ, Harvey HA, Lipton A, Simmonds M, Feil PD, Manders E, Davis TS. Marked heterogeneity of aromatase activity in human malignant melanoma tissue. Eur J Cancer Clin Oncol. 1988 Dec; 24(12):1811-6.
|
|
|
|
|
68.
|
Lipton A, Santen RJ, Santner SJ, Harvey HA, White-Hershey D, Bartholomew MJ, Sharkey FE. Correlation of aromatase activity with histological differentiation of breast cancer--a morphometric analysis. Breast Cancer Res Treat. 1988 Sep; 12(1):31-5.
|
|
|
|
|
69.
|
Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon R, et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol. 1988 Sep; 6(9):1456-66.
|
|
|
|
|
70.
|
Houts PS, Yasko JM, Harvey HA, Kahn SB, Hartz AJ, Hermann JF, Schelzel GW, Bartholomew MJ. Unmet needs of persons with cancer in Pennsylvania during the period of terminal care. Cancer. 1988 Aug 1; 62(3):627-34.
|
|
|
|
|
71.
|
Perez R, Lipton A, Harvey HA, Simmonds MA, Romano PJ, Imboden SL, Giudice G, Downing MR, Alton NK. A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy. J Biol Response Mod. 1988 Jun; 7(3):309-17.
|
|
|
|
|
72.
|
Hessan H, Houck J, Harvey H. Airway obstruction due to lymphoma of the larynx and trachea. Laryngoscope. 1988 Feb; 98(2):176-80.
|
|
|
|
|
73.
|
Schiller JH, Rasmussen P, Benson AB, Witte RS, Bockman RS, Harvey HA, Siris ES, Citrin DL, Greco FA, Stock JL. Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. Arch Intern Med. 1987 May; 147(5):963-6.
|
|
|
|
|
74.
|
Santen RJ, Boucher AE, Santner SJ, Henderson IC, Harvey H, Lipton A. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women. J Lab Clin Med. 1987 Mar; 109(3):278-89.
|
|
|
|
|
75.
|
Lipton A, Santner SJ, Santen RJ, Harvey HA, Feil PD, White-Hershey D, Bartholomew MJ, Antle CE. Aromatase activity in primary and metastatic human breast cancer. Cancer. 1987 Feb 15; 59(4):779-82.
|
|
|
|
|
76.
|
Lipton A, Santen RJ, Harvey HA, Manni A, Simmonds MA, White-Hershey D, Bartholomew MJ, Walker BK, Dixon RH, Valdevia DE, et al. A randomized trial of aminoglutethimide +/- estrogen before chemotherapy in advanced breast cancer. Am J Clin Oncol. 1987 Feb; 10(1):65-70.
|
|
|
|
|
77.
|
Manni A, Santen RJ, Boucher AE, Lipton A, Harvey H, Simmonds M, Gordon R, Rohner T, Drago J, Wettlaufer J. Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer. J Steroid Biochem. 1987; 27(1-3):551-6.
|
|
|
|
|
78.
|
Messeih AA, Schweitzer JM, Lipton A, Harvey HA, Simmonds MA, Stryker JA, Ricci JA, Hoffman SL, Gottleib RJ, Dixon RH, et al. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat Rep. 1987 Jan; 71(1):61-6.
|
|
|
|
|
79.
|
Manni A, Santen RJ, Boucher AE, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon RA, Rohner TJ, Drago J, et al. Androgen priming and response to chemotherapy in advanced prostatic cancer. J Urol. 1986 Dec; 136(6):1242-6.
|
|
|
|
|
80.
|
Manni A, Santen RJ, Boucher AE, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon RA, Rohner T, Drago J, et al. Hormone stimulation and chemotherapy in advanced prostate cancer: interim analysis of an ongoing randomized trial. Anticancer Res. 1986 Mar-Apr; 6(2):309-14.
|
|
|
|
|
81.
|
Manni A, Santen R, Harvey H, Lipton A, Max D. Treatment of breast cancer with gonadotropin-releasing hormone. Endocr Rev. 1986 Feb; 7(1):89-94.
|
|
|
|
|
82.
|
Santen RJ, Manni A, Harvey H. Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma. Breast Cancer Res Treat. 1986; 7(3):129-45.
|
|
|
|
|
83.
|
Harvey HA, Lipton A, Santen RJ. Clinical studies with aminoglutethimide in advanced breast carcinoma. Acta Clin Belg Suppl. 1986; 11:29-40.
|
|
|
|
|
84.
|
Romano CF, Lipton A, Harvey HA, Simmonds MA, Romano PJ, Imboden SL. A phase II study of Catrix-S in solid tumors. J Biol Response Mod. 1985 Dec; 4(6):585-9.
|
|
|
|
|
85.
|
Messeih AA, Lipton A, Santen RJ, Harvey HA, Boucher AE, Murray R, Ragaz J, Buzdar AU, Nagel GA, Henderson IC. Aminoglutethimide-induced hematologic toxicity: worldwide experience. Cancer Treat Rep. 1985 Sep; 69(9):1003-4.
|
|
|
|
|
86.
|
Harvey HA, Lipton A, Max DT, Pearlman HG, Diaz-Perches R, de la Garza J. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J Clin Oncol. 1985 Aug; 3(8):1068-72.
|
|
|
|
|
87.
|
Wolf LM, Leitzel KE, Pegg AE, Harvey HA, Lipton A. The in vitro interaction of alpha-difluoromethyl ornithine (DFMO) and several interferons on human cell lines. J Biol Response Mod. 1985 Aug; 4(4):391-5.
|
|
|
|
|
88.
|
Drago JR, Rohner T, Santen R, Manni A, Lipton A, Harvey H, English H. Leuprolide: a review of its effects in animals and man. Br J Clin Pract Suppl. 1985 Mar; 37:4-7, 16-9.
|
|
|
|
|
89.
|
Manni A, Santen RJ, Boucher A, Lipton A, Harvey H, Simmonds M, White D, Gordon R, Ronher T, Drago J, et al. Hormone stimulation and chemotherapy in advanced prostate cancer: preliminary results of a prospective controlled clinical trial. Anticancer Res. 1985 Mar-Apr; 5(2):161-5.
|
|
|
|
|
90.
|
Drago JR, Rohner T, Santen R, Manni A, English H, Lipton A, Harvey H. Leuprolide: a review of its effects in animals and man. Br J Clin Pract. 1985 Feb; 39(2):77-9.
|
|
|
|
|
91.
|
Simmonds MA, Lipton A, Harvey HA, Ellison N, White DS. Phase II study of mitolactol in metastatic malignant melanoma. Cancer Treat Rep. 1985 Jan; 69(1):65-7.
|
|
|
|
|
92.
|
Santen RJ, English H, Rohner T, Drago J, Lipton A, Harvey H, Simmonds M, Boucher A, Glode LM, Wettlaufer J, et al. Androgen depletion/repletion in combination with chemotherapy: strategy for secondary treatment of metastatic prostatic cancer. Prog Clin Biol Res. 1985; 185A:359-71.
|
|
|
|
|
93.
|
Issell BF, Einhorn LH, Comis RL, Lawson RD, Baker LH, Harvey HA, Lanzotti VA, Wampler GL, Daniels JR, Anderson PN, et al. Multicenter Phase II trial of etoposide in refractory small cell lung cancer. Cancer Treat Rep. 1985 Jan; 69(1):127-8.
|
|
|
|
|
94.
|
Houts PS, Lipton A, Harvey HA, Martin B, Simmonds MA, Dixon RH, Longo S, Andrews T, Gordon RA, Meloy J, et al. Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer. 1984 Jun 1; 53(11):2388-92.
|
|
|
|
|
95.
|
Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep. 1984 Jun; 68(6):887-9.
|
|
|
|
|
96.
|
Manni A, Santen RJ, Boucher AE, Lipton A, Harvey H, Drago J, Rohner T, Haagensen D, Glode M, Santner SJ. Evaluation of CEA and GCDFP-15 plasma level during hormonally induced cancer stimulation. Anticancer Res. 1984 May-Jun; 4(3):141-4.
|
|
|
|
|
97.
|
Drago JR, Santen RJ, Lipton A, Worgul TJ, Harvey HA, Boucher A, Manni A, Rohner TJ. Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer. 1984 Apr 1; 53(7):1447-50.
|
|
|
|
|
98.
|
Jorge E, Harvey HA, Simmonds MA, Lipton A, Joehl RJ. Symptomatic malignant melanoma of the gastrointestinal tract. Operative treatment and survival. Ann Surg. 1984 Mar; 199(3):328-31.
|
|
|
|
|
99.
|
Orsini MA, Strauss M, Zaino RJ, Messeih AA, Harvey HA, Lipton A. Treatment of advanced epidermoid carcinoma of the head and neck using methotrexate, bleomycin and cis-platinum. Trans Pa Acad Ophthalmol Otolaryngol. 1984; 37(1):71-6.
|
|
|
|
|
100.
|
Wolf LM, Leitzel KE, Harvey HA, Lipton A. The in vitro interaction of RA-233 and several interferons on human cell lines. J Med. 1984; 15(1):15-21.
|
|
|
|
|
101.
|
Strauss M, Towfighi J, Lord S, Lipton A, Harvey HA, Brown B. Cis-platinum ototoxicity: clinical experience and temporal bone histopathology. Laryngoscope. 1983 Dec; 93(12):1554-9.
|
|
|
|
|
102.
|
Hatae Y, Hatae T, Lipton A, Harvey H, McCarthy M, Davidson EA. Radioimmunoassay of a cancer-related glycoprotein. Circulating levels. Carbohydr Res. 1983 Oct 28; 122(2):295-303.
|
|
|
|
|
103.
|
Houts PS, Lipton A, Harvey HA, Martin BA. A method for collecting detailed data on direct and indirect medical expenses of cancer patients. Prog Clin Biol Res. 1983; 120:193-9.
|
|
|
|
|
104.
|
Lipton A, Harvey HA, Lawrence B, Gottlieb R, Kukrika M, Dixon R, Graham W, Miller S, Heckard R, Schelzel D, White DS. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer. 1983 Jan 1; 51(1):57-60.
|
|
|
|
|
105.
|
Worgul TJ, Santen RJ, Samojlik E, Veldhuis JD, Lipton A, Harvey HA, Drago JR, Rohner TJ. Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. J Urol. 1983 Jan; 129(1):51-5.
|
|
|
|
|
106.
|
Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G, Shafik A. A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer. 1982 Dec 1; 50(11):2265-8.
|
|
|
|
|
107.
|
Harvey HA, Lipton A, Lawrence BV, White DS, Wells SA, Blumenschein G, Lee D. Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol. 1982 Sep; 21(1):42-4.
|
|
|
|
|
108.
|
Strauss M, Conner GH, Harvey HA, White DS. Aerodigestive tract papillomatosis: bacille Calmette-Guérin (BCG) immunotherapy. Laryngoscope. 1982 Sep; 92(9 Pt 1):971-5.
|
|
|
|
|
109.
|
Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G, Shafik A. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res. 1982 Aug; 42(8 Suppl):3434s-3436s.
|
|
|
|
|
110.
|
Wells SA, Worgul TJ, Samojlik E, Boucher AE, Lipton A, Harvey H, White D, Smart E, Cox C, Santen RJ. Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast. Cancer Res. 1982 Aug; 42(8 Suppl):3454s-3457s.
|
|
|
|
|
111.
|
Santen RJ, Worgul TJ, Samojlik E, Boucher AE, Lipton A, Harvey H. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses. Cancer Res. 1982 Aug; 42(8 Suppl):3397s-3401s.
|
|
|
|
|
112.
|
Lipton A, Harvey HA, Santen RJ. Closing remarks to the conference, Aromatase: New Perspectives for Breast Cancer. Cancer Res. 1982 Aug; 42(8 Suppl):3468s.
|
|
|
|
|
113.
|
Harvey HA, Lipton A, White DS, Santen RJ, Boucher AE, Shafik AS, Dixon RJ. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res. 1982 Aug; 42(8 Suppl):3451s-3453s.
|
|
|
|
|
114.
|
Wynert WR, Harvey HA, Lipton A, Schweitzer J, White DS. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione). Cancer Treat Rep. 1982 Jun; 66(6):1303-6.
|
|
|
|
|
115.
|
Brenner DE, Harvey HA, Lipton A, Demers L. A study of prostaglandin E2, parathormone, and response to indomethacin in patients with hypercalcemia of malignancy. Cancer. 1982 Feb 1; 49(3):556-61.
|
|
|
|
|
116.
|
Santen RJ, Lipton A, Harvey H, Wells SA. Use of aminoglutethimide and hydrocortisone as a "medical adrenalectomy" for treatment of breast carcinoma. Prog Clin Cancer. 1982; 8:245-65.
|
|
|
|
|
117.
|
Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A, Samojlik E, Wells SA. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med. 1982 Jan; 96(1):94-101.
|
|
|
|
|
118.
|
Lipton A, Scialla S, Harvey H, Dixon R, Gordon R, Hamilton R, Ramsey H, Weltz M, Heckard R, White D. Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. J Med. 1982; 13(5-6):419-29.
|
|
|
|
|
119.
|
Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med. 1981 Sep 3; 305(10):545-51.
|
|
|
|
|
120.
|
Harvey HA, Lipton A, Lawrence BV. Raynaud's phenomenon with vinblastine and bleomycin. Ann Intern Med. 1981 Apr; 94(4 pt 1):542-3.
|
|
|
|
|
121.
|
Harvey HA, Lipton A, White D, Davidson E. Glycoproteins and human cancer: II. Correlation between circulating level and disease status. Cancer. 1981 Jan 15; 47(2):324-7.
|
|
|
|
|
122.
|
Lawrence BV, Lipton A, Harvey HA, Santen RJ, Wells SA, Cox CE, White DS, Smart EK. Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. Cancer. 1980 Feb 15; 45(4):786-91.
|
|
|
|
|
123.
|
Harvey HA, Santen RJ, Osterman J, Samojlik E, White DS, Lipton A. A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer. 1979 Jun; 43(6):2207-14.
|
|
|
|
|
124.
|
Lipton A, Harvey HA, Delong S, Allegra J, White D, Allegra M, Davidson EA. Glycoproteins and human cancer. 1. Circulating levels in cancer serum. Cancer. 1979 May; 43(5):1766-71.
|
|
|
|
|
125.
|
Kane R, Harvey H, Andrews T, Bernath A, Curry S, Dixon R, Gottlieb R, Kukrika M, Lipton A, Mortel R, Ricci J, White D. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma. Cancer Treat Rep. 1979 Feb; 63(2):307-9.
|
|
|
|
|
126.
|
Santen RJ, Veldhuis J, Samojlik E, Lipton A, Harvey H, Wells SA. Mechanism of action of aminoglutethimide in breast cancer. Lancet. 1979 Jan 6; 1(8106):44-5.
|
|
|
|
|
127.
|
Holzer D, Harvey HA, Lipton A. Comparison of DES vs DES + chlorambucil in women with first recurrence of breast cancer. J Surg Oncol. 1979; 12(1):1-9.
|
|
|
|
|
128.
|
Lawrence B, Santen RJ, Lipton A, Harvey HA, Hamilton R, Mercurio T. Pancytopenia induced by aminoglutethimide in the treatment of breast cancer. Cancer Treat Rep. 1978 Oct; 62(10):1581-3.
|
|
|
|
|
129.
|
Wells SA, Santen RJ, Lipton A, Haagensen DE, Ruby EJ, Harvey H, Dilley WG. Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg. 1978 May; 187(5):475-84.
|
|
|
|
|
130.
|
Lipton A, Hepner GW, White DS, Harvey HA. Decreased hepatic drug demethylation in patients receiving chemo-immunotherapy. Cancer. 1978 May; 41(5):1680-4.
|
|
|
|
|
131.
|
Hepner GW, Vesell ES, Lipton A, Harvey HA, Wilkinson GR, Schenker S. Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med. 1977 Sep; 90(3):440-56.
|
|
|
|
|
132.
|
Teutsch C, Lipton A, Harvey HA. Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep. 1977 Aug; 61(5):925-6.
|
|
|
|
|
133.
|
Santen RJ, Samojlik E, Lipton A, Harvey H, Ruby EB, Wells SA, Kendall J. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer. 1977 Jun; 39(6 Suppl):2948-58.
|
|
|
|
|
134.
|
Harvey HA, Allegra JC, Demers LM, Luderer JR, Brenner DE, Trautlein JJ, White DS, Gillin MA, Lipton A. Immunosuppression and human cancer: role of prostaglandins. Cancer. 1977 Jun; 39(6):2362-4.
|
|
|
|
|
135.
|
Mortel R, Allegra JC, Demers LM, Harvey HA, Trautlein J, Nahhas W, White D, Gillin MA, Lipton A. Plasma prostaglandins across the tumor bed of patients with gynecologic malignancy. Cancer. 1977 May; 39(5):2201-3.
|
|
|
|
|
136.
|
Demers LM, Allegra JC, Harvey HA, Lipton A, Luderer JR, Mortel R, Brenner DE. Plasma prostaglandins in hypercalcemic patients with neoplastic disease. Cancer. 1977 Apr; 39(4):1559-62.
|
|
|
|
|
137.
|
Hepner GW, Uhlin SR, Lipton A, Harvey HA, Rohrer V. Abnormal aminopyrine metabolism in patients with hepatic neoplasm. Detection by breath test. JAMA. 1976 Oct 4; 236(14):1587-90.
|
|
|
|
|
138.
|
Lipton A, Sheehan L, Mortel R, Harvey HA. Urinary polyamine levels in patients with localized malignancy. Cancer. 1976 Sep; 38(3):1344-7.
|
|
|
|
|
139.
|
Allegra J, Lipton A, Harvey H, Luderer J, Brenner D, Mortel R, Demers L, Gillin M, White D, Trautlein J. Decreased prevalence of immediate hypersensitivity (atopy) in a cancer population. Cancer Res. 1976 Sep; 36(9 pt.1):3225-6.
|
|
|
|
|
140.
|
Park CH, Miller FJ, Lipton A, Harvey H. Incidentally detected thrombosed vein during 67Ga citrate scanning. AJR Am J Roentgenol. 1976 Jun; 126(6):1249-50.
|
|
|
|
|
141.
|
Lipton A, Sheehan L, Harvey HA. Urinary polyamine levels in patients with gastrointestinal malignancy. Cancer. 1975 Dec; 36(6 Suppl):2351-4.
|
|
|
|